Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Timing of Blad-Care for BCG-Induced Bladder Toxicity in NMIBC
NCT07495072Recruiting
- Sponsor
- Bloomage Biotech
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Hydrogel Systems, Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of Blad-Care in cystitis (2 arms), sponsored by Bloomage Biotech. Primary endpoint: Combined Interstitial Cystitis Symptom Index and Interstitial Cystitis Problem Index at 14 weeks. Started Nov 2025; status: recruiting.
02
Drugs
Blad-Care
03
Conditions
cystitis
Beyond the preview
Go deeper on NCT07495072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495072.